What is Singulex?
Founded in 1997 and headquartered in Alameda, California, Singulex is at the forefront of developing and providing single-molecule counting technology. This advanced capability is crucial for both clinical diagnostics, enabling more precise disease detection and monitoring, and for scientific discovery, empowering researchers with unprecedented sensitivity in their experiments. The company's technology addresses a critical need for higher sensitivity and accuracy in biological analysis, positioning it as a key player in the evolving landscape of healthcare and life sciences.
How much funding has Singulex raised?
Singulex has raised a total of $151.8M across 6 funding rounds:
Series C
$8.4M
Series D
$19M
Series E
$19M
Series F
$15.3M
Debt
$40M
Private Equity
$50M
Series C (2006): $8.4M with participation from Prolog Capital, Fisk Ventures, and BioProfile Holding Company
Series D (2009): $19M led by Jafco ventures and OrbiMed
Series E (2009): $19M supported by Fisk Ventures, OrbiMed, and JAFCO Japan
Series F (2012): $15.3M, investors not publicly disclosed
Debt (2013): $40M backed by Oxford Finance and Silicon Valley Bank
Private Equity (2016): $50M with participation from Grifols
Key Investors in Singulex
Grifols
Grifols is a global healthcare company with a strong focus on plasma-derived medicines, diagnostics, and hospital products. Their investment in Singulex likely aligns with their strategy to enhance diagnostic capabilities and expand their presence in innovative healthcare solutions.
Oxford Finance
Oxford Finance is a specialty finance firm providing flexible financial solutions to healthcare and life sciences companies. Their participation suggests confidence in Singulex's business model and its potential for significant returns within the life sciences sector.
Silicon Valley Bank
Silicon Valley Bank (SVB) is a prominent financial institution supporting technology and life sciences companies. Their involvement indicates Singulex's strong standing within the innovation ecosystem and provides access to valuable financial services and networks.
What's next for Singulex?
The recent major strategic investment in Singulex signals a strong validation of its technology and market potential. This capital infusion is expected to accelerate product development, expand market reach, and enhance manufacturing capabilities. As Singulex moves forward, its focus will likely be on leveraging this strategic backing to solidify its leadership in the single-molecule counting space, potentially exploring new applications and partnerships to further its mission of improving clinical diagnostics and scientific understanding.
See full Singulex company page
